U.S. Food and Drug Administration (2011) FDA Drug Safety Communication: Severe Liver Injury Associated with the Use of Dronedarone (Marketed as Multaq). U.S. Food and Drug Administration, Maryland.
http://www.fda.gov/drugs/drugsafety/ucm240011.htm

has been cited by the following article:

• TITLE: A Review of Structure Activity Relationship of Amiodarone and Its Derivatives

  AUTHORS: Moiz A. Siddiqui, Amjad Khan, Mehreen Zaka

  KEYWORDS: Amiodarone, Dronedarone, Structure-Activity-Relationship

  JOURNAL NAME: Open Journal of Medicinal Chemistry, Vol.6 No.2, June 30, 2016

  ABSTRACT: Structure Activity Relationship forms the basis of Rational Drug Design in the circles of pharmaceutical and medicinal chemistry. Appropriate knowledge of functional outcomes of structural modifications is crucial in conferring desired pharmacological properties to a chemical compound. Amiodarone is a classical antiarrythmic agent with a long list of adverse effects. This article attempts to review the structure activity relationship of some of the homologues of amiodarone in order to determine the most clinically desirable molecule.